Immunohistochemical (IHC) analysis of the primary and the matched metastatic tumors from the tamoxifen-treated endocrine resistant xenografts showed expression of ER, as well as the proliferation marker Ki67, in both the primary and metastatic tumors (Fig. 3c). Here, MKI67 is linked to metastatic neoplasm.